West Nile Virus Clinical Trial
Official title:
Pharmacokinetic Study of AVI-4020 in Cerebral Spinal Fluid Among Healthy Adult Males Following Intravenous Administration
Verified date | July 2009 |
Source | Sarepta Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
During a clinical study of people with severe West Nile virus infections, it was determined
that the drug AVI-4020 crossed the blood-brain barrier. This study will assess the amount of
drug that goes across the blood-brain barrier and the drug levels measured in both the blood
and urine.
The objective of this study is to find out how much and how fast this drug crosses this
barrier.
Status | Completed |
Enrollment | 14 |
Est. completion date | June 2009 |
Est. primary completion date | December 2006 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 64 Years |
Eligibility |
Inclusion Criteria: - Adult males 18 years to 64 years of age; - Good general health (as evidenced by no chronic conditions, normal physical exam, vital signs within normal limits; laboratory evaluations within normal range) - Signed and dated written informed consent form; and - Willing to participate in all study activities and all requirements, including effective contraception (viz., a double-barrier method) during the 7-day study surveillance period. Exclusion Criteria: - Hematology, serum chemistry (exclusive of electrolytes), and urinalysis laboratory test values >2 times upper limits of normal or anemia (hemoglobulin <11 g/dL), leukopenia (total white blood count <3,000/µL or total neutrophils <1,500/ µL) or thrombocytopenia (platelets <100,000/µL). Electrolytes and coagulation values exceeding normal ranges are to be excluded. - Body Mass Index (BMI) >35. - Calculated creatinine clearance (by the Cockroft and Gault Formula) <70 mL/min, based on age and gender. - Positive HIV-1 or HIV-2 serology. - Positive HCV serology and/or positive plasma HCV-RNA status. - Positive Hepatitis B status. - Solid or hematopoetic organ transplant recipient. - Active illness or recent illness within 30 days of the first dose of study drug. - History of any of the following: brain injury, neoplasm, chronic or migraine headaches, cancer, meningitis or hydrocephalus. - Usage of any prescribed, over-the-counter or illicit drug(s) within 30 days of study drug administration. Use of herbal remedies and/or supplements at the discretion of the Investigator. - Unwilling to practice effective contraception during the study period. - Participation in any clinical interventional trial within the previous 6 months. - Positive drug urine screen. |
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | NW Kinetics | Tacoma | Washington |
Lead Sponsor | Collaborator |
---|---|
Sarepta Therapeutics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine if the study drug penetrates the blood brain barrier following a single dose of AVI-4020, and if it does, the associated CSF, plasma and urine pharmacokinetics | |||
Secondary | Safety, Tolerability |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00069316 -
Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease
|
Phase 2 | |
Completed |
NCT00097006 -
Retrovirus Epidemiology Donor Study-II (REDS-II)
|
N/A | |
Completed |
NCT00138463 -
West Nile Virus Natural History
|
N/A | |
Completed |
NCT00068055 -
IVIG - West Nile Encephalitis: Safety and Efficacy
|
Phase 1/Phase 2 | |
Completed |
NCT00069303 -
Natural History of West Nile Virus Infection
|
N/A | |
Withdrawn |
NCT04371003 -
Prospective Investigation of Oxidative Stress in West Nile Virus Infection
|
||
Completed |
NCT05294003 -
West Nile Virus Seroprevalence Under Bird Ringers
|
||
Completed |
NCT02186626 -
Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age
|
Phase 1 | |
Completed |
NCT00515385 -
A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults
|
Phase 1 |